A carregar...
A multicenter phase II study of Q3 week or weekly paclitaxel in combination with bevacizumab for the treatment of metastatic or unresectable angiosarcoma
Paclitaxel (P) and bevacizumab (B) are agents that provide clinical benefit in advanced angiosarcoma (AS). The objective of this study was to assess the efficacy and safety of P-B in two different scheduled regimens. Patients were to receive P 200mg/m2 IV with B 15mg/kg IV every 21 days (Regimen A)...
Na minha lista:
| Publicado no: | Rare Tumors |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5946584/ https://ncbi.nlm.nih.gov/pubmed/29760870 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2036361318771771 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|